Clearmind Medicine shares surge 26.48% premarket on positive trial data, DSMB approval, and expanded clinical site enrollment.

Clearmind Medicine Inc. surged 26.5% in premarket trading following three pivotal developments in its FDA-approved Phase I/IIa trial for CMND-100, a non-hallucinogenic oral therapy targeting Alcohol Use Disorder (AUD). The company reported positive top-line data from the first cohort of six participants across elite sites like Johns Hopkins and Yale, followed by unanimous approval from the independent Data and Safety Monitoring Board (DSMB) to continue the trial. Additionally, enrollment began at Tel Aviv Sourasky Medical Center in Israel, accelerating multinational recruitment. These milestones, including safety validation and expanded trial capacity, underscored progress in addressing a $249 billion annual public health burden, bolstering investor confidence in the therapy’s potential.